1
|
Buchstaller HP, Sala-Hojman A, Leiendecker M, Albers J, Anlauf U, Berges N, Dong L, Fuchß T, Germann M, Knehans T, Krier M, Lecomte M, Müller D, Müller SR, Leuthner B, Lindemann R, Musil D, Nowak M, Reither V, Rettig C, Schindler CEM, Pakulska U, Spuck D, Wegener A, Zarębski A. Discovery of Cycloalkyl[ c]thiophenes as Novel Scaffolds for Hypoxia-Inducible Factor-2α Inhibitors. J Med Chem 2023. [PMID: 37403966 DOI: 10.1021/acs.jmedchem.3c00332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/06/2023]
Abstract
Hypoxia-inducible factors (HIFs) are heterodimeric transcription factors induced in diverse pathophysiological settings. Inhibition of HIF-2α has become a strategy for cancer treatment since the discovery that small molecules, upon binding into a small cavity of the HIF-2α PAS B domain, can alter its conformation and disturb the activity of the HIF dimer complex. Herein, the design, synthesis, and systematic SAR exploration of cycloalkyl[c]thiophenes as novel HIF-2α inhibitors are described, providing the first chemotype featuring an alkoxy-aryl scaffold. X-ray data confirmed the ability of these inhibitors to induce perturbation of key amino acids by appropriately presenting key pharmacophoric elements in the hydrophobic cavity. Selected compounds showed inhibition of VEGF-A secretion in cancer cells and prevention of Arg1 expression and activity in IL4-stimulated macrophages. Moreover, in vivo target gene modulation was demonstrated with compound 35r. Thus, the disclosed HIF-2α inhibitors represent valuable tools for investigating selective HIF-2α inhibition and its effect on tumor biology.
Collapse
Affiliation(s)
| | - Ada Sala-Hojman
- Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | | | - Joachim Albers
- Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Uwe Anlauf
- Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Nina Berges
- Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Liming Dong
- Pharmaron, Beijing Headquartes, 6 Taihe Road, BDA, 100176 Beijing, China
| | - Thomas Fuchß
- Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Martina Germann
- Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Tim Knehans
- Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Mireille Krier
- Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Marc Lecomte
- Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Daniel Müller
- Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Sandra R Müller
- Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Birgitta Leuthner
- Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Ralph Lindemann
- Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Djordje Musil
- Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Mateusz Nowak
- Ryvu Therapeutics S.A., 2 Sternbacha Street, 30-394 Krakow, Poland
| | - Vivian Reither
- Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Corinna Rettig
- Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | | | - Urszula Pakulska
- Ryvu Therapeutics S.A., 2 Sternbacha Street, 30-394 Krakow, Poland
| | - Dieter Spuck
- Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Ansgar Wegener
- Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Adrian Zarębski
- Ryvu Therapeutics S.A., 2 Sternbacha Street, 30-394 Krakow, Poland
| |
Collapse
|
2
|
Buchstaller HP, Anlauf U, Dorsch D, Kögler S, Kuhn D, Lehmann M, Leuthner B, Lodholz S, Musil D, Radtki D, Rettig C, Ritzert C, Rohdich F, Schneider R, Wegener A, Weigt S, Wilkinson K, Esdar C. Optimization of a Screening Hit toward M2912, an Oral Tankyrase Inhibitor with Antitumor Activity in Colorectal Cancer Models. J Med Chem 2021; 64:10371-10392. [PMID: 34255518 DOI: 10.1021/acs.jmedchem.1c00800] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Constitutive activation of the canonical Wnt signaling pathway, in most cases driven by inactivation of the tumor suppressor APC, is a hallmark of colorectal cancer. Tankyrases are druggable key regulators in these malignancies and are considered as attractive targets for therapeutic interventions, although no inhibitor has been progressed to clinical development yet. We continued our efforts to develop tankyrase inhibitors targeting the nicotinamide pocket with suitable drug-like properties for investigating effects of Wnt pathway inhibition on tumor growth. Herein, the identification of a screening hit series and its optimization through scaffold hopping and SAR exploration is described. The systematic assessment delivered M2912, a compound with an optimal balance between excellent TNKS potency, exquisite PARP selectivity, and a predicted human PK compatible with once daily oral dosing. Modulation of cellular Wnt pathway activity and significant tumor growth inhibition was demonstrated with this compound in colorectal xenograft models in vivo.
Collapse
Affiliation(s)
- Hans-Peter Buchstaller
- Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Uwe Anlauf
- Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Dieter Dorsch
- Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Sarah Kögler
- Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Daniel Kuhn
- Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Martin Lehmann
- Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Birgitta Leuthner
- Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Sara Lodholz
- Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Djordje Musil
- Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Daniela Radtki
- Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Corinna Rettig
- Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Claudio Ritzert
- Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Felix Rohdich
- Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Richard Schneider
- Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Ansgar Wegener
- Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Stefan Weigt
- Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Kai Wilkinson
- Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Christina Esdar
- Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| |
Collapse
|
3
|
Buchstaller HP, Anlauf U, Dorsch D, Kuhn D, Lehmann M, Leuthner B, Musil D, Radtki D, Ritzert C, Rohdich F, Schneider R, Esdar C. Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity. J Med Chem 2019; 62:7897-7909. [DOI: 10.1021/acs.jmedchem.9b00656] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Affiliation(s)
- Hans-Peter Buchstaller
- Merck Healthcare KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Uwe Anlauf
- Merck Healthcare KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Dieter Dorsch
- Merck Healthcare KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Daniel Kuhn
- Merck Healthcare KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Martin Lehmann
- Merck Healthcare KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Birgitta Leuthner
- Merck Healthcare KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Djordje Musil
- Merck Healthcare KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Daniela Radtki
- Merck Healthcare KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Claudio Ritzert
- Merck Healthcare KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Felix Rohdich
- Merck Healthcare KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Richard Schneider
- Merck Healthcare KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Christina Esdar
- Merck Healthcare KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| |
Collapse
|
4
|
Buchstaller HP, Anlauf U. Parallel Solution-Phase Synthesis of a 2-Aminothiazole Library Including Fully Automated Work-Up. Comb Chem High Throughput Screen 2011; 14:104-8. [DOI: 10.2174/138620711794474024] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2010] [Accepted: 10/27/2010] [Indexed: 11/22/2022]
|
5
|
|
6
|
|